JeanMarie Guenot is a pharmaceutical executive from San Francisco Bay Area. She has a postgraduate degree in business administration from the University of Pennsylvania and a Ph.D. from the University of California. She is skilled in the fields of biotechnology and pharmaceuticals. She is trained in medicinal chemistry with a major focus on protein structure prediction, methods for molecular dynamics, drug designs, x-ray, and NMR refinement.
Dr. Guenot’s career in the Pharmaceutical world
JeanMarie is the current executive principal of the globally renowned Amphivena Therapeutics, Inc. Her role in this company is to assist in eradicating cancer through the development of innovative bifunctional antibody therapies for hematologic tumors. At Amphivena Therapeutics, Inc., she works with other successful women such as Lori Kunkel, Jenifer Sims, Judith Fox, and Dr. Susan Jones. Aside from conducting research, she has unparalleled expertise in the development of startups. Dr. Guenot has two decades of work experience in venture capital, business development, commercial development, and project & alliance management.
CrunchBase.com illustrates how Dr. JeanMarie Guenot began her career as a pharmaceutical business associate, in 1993, at Hoffman-La Roche. In 2000, she took up another job at Atlas Venture where her duties were to build life science companies. She was in charge of managing venture capital investments for various clients. In 2003, PDL Biopharma appointed her as the vice president. She was given the task of managing corporate and business development strategies. At PDL, she facilitated an 800 million dollar transaction that saw commercialization of Biogen Idec-PDL 50:50, a popular cancer drug. Additionally, she oversaw the development of product portfolios, licensing of products, and mergers and acquisition transactions.
Dr. Guenot established two prominent companies
In 2008, Dr. Guenot co-founded Guenot, LLC and she served as the managing partner of the company. A year later, she established SKS Ocular LLC., an ophthalmic company. SKS Ocular LLC conducts research on macular degeneration, sustained release of ocular drug delivery, ocular inflammation, and therapeutics for glaucoma. The key drivers of her success are integrity, hard work, intelligence, and experience in managing of both public and private companies. Dr. Guenot practices an open and consultative style of management.